Chronic Hepatitis B Market Report 2024

The chronic hepatitis B market size has grown steadily in recent years. It will grow from $3.62 billion in 2023 to $3.77 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth during the historic period was driven by advancements in antiviral therapy, increased efforts from governments and NGOs, enhanced diagnostic techniques, a rising incidence of HIV, and heightened awareness.

The chronic hepatitis B market size is expected to see steady growth in the next few years. It will grow to $4.47 billion in 2028 at a compound annual growth rate (CAGR) of 4.3%. Anticipated growth in the forecast period will be fueled by expanding opportunities in emerging markets, supportive government policies and funding, advancements in diagnostics and screening technologies, rising healthcare spending, increased strategic partnerships and collaborations, a growing elderly population, and heightened public awareness campaigns. Key trends expected in this period include a shift towards curative treatments, expansion into emerging markets, improvements in diagnostics and screening, fostering partnerships and collaborations, and a focus on patient-centered care.

The high prevalence of chronic hepatitis B infection is anticipated to drive the growth of the chronic hepatitis B virus market in the future. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV) and can be prevented through vaccination. The increase in hepatitis B infection rates is particularly evident in low- and middle-income countries, where low vaccination coverage leads to higher transmission rates as large portions of the population remain unprotected. This rising infection rate increases the demand for diagnostic tests and treatment options. For example, according to the European Centre for Disease Prevention and Control, a Sweden-based agency, there were 16,187 cases of hepatitis B virus (HBV) infection recorded in 30 Eastern European Member States in 2021. The total cases amount to 15,380, which is a crude rate of 4.7 cases per 100,000 people, compared to 14,332 cases in 2020. Thus, the high prevalence of hepatitis B infection will boost the chronic hepatitis B virus market.

Major companies in the chronic hepatitis B market are adopting strategic partnerships to enhance their technological capabilities and market reach. A strategic partnership involves a collaborative relationship between two or more organizations that combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in January 2021, Gilead Sciences Inc., a US-based biopharmaceutical company, collaborated with VIR Biotechnology, a US-based biotech company, to explore novel combination therapies aimed at achieving a functional cure for chronic hepatitis B virus (HBV). They will start a Phase 2 trial assessing various combinations of Gilead’s investigational TLR-8 agonist, selgantolimod, Vir’s investigational siRNA, VIR-2218, and a commercially available PD-1 antagonist. Additionally, treatment-experienced patients may receive Gilead’s Vemlidy (tenofovir alafenamide fumarate, TAF). The primary goal of the trial is to determine the percentage of patients achieving a functional cure, characterized by the disappearance of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum off-therapy.

In November 2023, GSK plc, a pharmaceutical company headquartered in the UK, acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. The acquisition includes the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug. Through this acquisition, GSK aims to enrich its portfolio and reinforce its position in the treatment of chronic hepatitis B by introducing a promising new therapy. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson based in Belgium, specializes in developing treatments for a range of serious and complex diseases, including infectious diseases such as chronic hepatitis B.

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals.

North America was the largest region in the chronic hepatitis B market in 2023. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic hepatitis b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic hepatitis B results from a prolonged infection with the hepatitis B virus (HBV), lasting more than six months. It can potentially cause severe liver damage, liver failure, or liver cancer. While often asymptomatic for years, it can be identified through blood tests and requires ongoing management with antiviral medications and regular monitoring.

In treating chronic hepatitis B, medications primarily consist of antivirals and immunomodulators. Antivirals are specifically designed to hinder the replication and growth of viruses. They play a crucial role in managing chronic hepatitis B by reducing the viral load in the liver and slowing the progression of liver damage.

The chronic hepatitis B market research report is one of a series of new reports that provides chronic hepatitis B market statistics, including chronic hepatitis B industry global market size, regional shares, competitors with an chronic hepatitis B market share, detailed chronic hepatitis B market segments, market trends and opportunities, and any further data you may need to thrive in the chronic hepatitis B industry. This chronic hepatitis B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic hepatitis B market consists of revenues earned by entities by providing services such as diagnostic testing, treatments, liver function monitoring, patient education, and support programs.The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic hepatitis B market also includes sales of medications, interferons, liver transplant medications, diagnostic kits, liver biopsy equipment, and HBV vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.